Deal-Ticker: Kellerhals Carrard advises on CHF 122.5m capital increase and listing of 1'000'000 new shares of Ypsomed Holding on SIX Swiss Exchange

Frédéric Rochat, Beat Brechbühl, Philippe Frésard, Robin Juchler, Jörg von Manger-Koenig, Christian Witschi, Luca Bianchi, Reto Schumacher

The 1'000'000 new registered shares of Ypsomed Holding AG were successfully listed on the SIX Swiss Exchange. Ypsomed Group is a leading developer and manufacturer of injection and infusion systems for self-medication and a renowed diabetes specialist. Zürcher Kantonalbank acted as Sole Global Coordinator of this capital increase. The first trading day of the new registered shares was 28 June 2022.

Beat Brechbühl (Partner, Capital Markets), Frédéric Rochat (Partner, Capital Markets), Luca Bianchi (Partner, Capital Markets), Reto Schumacher (Partner, Corporate), Jörg von Manger-König (Of Counsel, Life Sciences), Philippe Frésard (Partner, Notary), Robin Juchler (Associate, Capital Markets) and Christian Witschi (Partner, Tax) of Kellerhals Carrard advised Ypsomed and Zürcher Kantonalbank as Counsel to the Transaction on the capital increase and listing.